Published in Biotech Business Week, July 6th, 2009
"However, there is evidence that the control of glucose-substrate flux is an important mechanism of the anti proliferative action of imatinib because imatinib-resistant gastrointestinal stromal KIT-positive tumors reveal highly elevated glucose...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.